On Friday, Following U.S. Stocks were among the “Top Losers”: Hibbett Sports, Inc (NASDAQ:HIBB), Windstream Holdings, Inc (NASDAQ:WIN), Citizens Financial Group Inc (NYSE:CFG), Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)
Hibbett Sports, Inc (NASDAQ:HIBB)’s shares dwindled -2.87%, and closed at $50.83. The company holds the market capitalization of 1.27B. For the trailing twelve months, the stock’s return on assets value is 22.80%, in response to its return on investment value of 31.80%. Its 20-day moving average gained 1.43%, above 50-day moving average of 3.55%, above 200-day moving average of 5.18% from the latest market price of $50.83. The mean recommendation of analysts for this stock is 2.80.(where 1=Buy, 5=Sale).
Hibbett Sports, Inc. operates sporting goods stores in small and mid-sized markets primarily in the south, Southwest, Mid-Atlantic, and the Midwest regions of the United States. The company’s stores offer a range of merchandise, counting athletic footwear, team sports equipment, athletic and fashion apparel, and related accessories. As of August 2, 2014, it operated 950 stores. The company, through its partner, Hibbett Team Sales, Inc., also sells its merchandise directly to educational institutions and youth associations. Hibbett Sports, Inc. was founded in 1945 and is based in Birmingham, Alabama.
Windstream Holdings, Inc (NASDAQ:WIN), declined -2.84%, and closed at $7.54. The stock has price to sale value of 0.78, however, price to book value is 19.84. With recent decline, the year-to-date (YTD) performance reflected a -8.50% declined below last year. During the past month the stocks gain 2.86%, bringing three-month performance to -15.66% and six-month performance to -29.80%. The mean recommendation of analysts for this stock is 3.00. (where 1=Buy, 5=Sale).
Windstream Holdings, Inc. provides communications and technology solutions in the United States. It offers managed services and cloud computing services to businesses, in addition to broadband, voice, and video services to consumers primarily in rural markets. The company’s primary business service offerings comprise integrated voice and data services, multi-site networking, data center services, managed services, high-speed Internet, and voice services. The company also sells and leases communications equipment systems tailored to customers’ needs, in addition to offers maintenance plans to support these systems.
Citizens Financial Group Inc (NYSE:CFG), dipped -2.82%, and closed at $24.77. The company has the market capitalization of $13.52B. In the last trading session 3.48M shares changed hands as compared to its average volume of 1.27M shares. On the other hand the stock’s volatility for the week is 2.17%, and for the month is 2.00%. The stock price to book value is $0.72; however price to sale value is $3.76. Analyst’s mean recommendation regarding this stock is 2.40. (where 1=Buy, 5=Sale).
Citizens Financial Group, Inc. operates as the bank holding company for Citizens Bank, N.A. and Citizens Bank of Pennsylvania, which provide consumer and commercial banking services in the United States. Its deposit products comprise on demand, checking with interest, regular savings, money market accounts, and term deposits. The company’s Consumer Banking segment focuses on retail customers and small businesses with traditional banking products and services, counting checking, savings, home loans, student loans, credit cards, business loans, and financial administration services.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC), dropped -2.78%, and closed at $1.05. The stock volatility for the week is 11.13%, while for the month remained 18.41%. The company holds consensus target price of $9.00.
If we consider EPS growth of the company, then we will notice the following observations:
The company showed -0.88 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 26.30%, and Annual EPS growth for the past 5 years is considered as 38.20%.
The mean recommendation of analysts for this stock is 3.00. (where 1=Buy, 5=Sale).
Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops and commercializes mechanism-targeted drugs to treat human cancers and other serious diseases. The company’s oncology development programs comprise sapacitabine, an orally-accessible nucleoside analogue that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and seliciclib, an orally-accessible 2nd generation CDK inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
